{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T19:52:39Z","timestamp":1793649159742,"version":"4.5.1"},"reference-count":50,"publisher":"American Society of Hematology","issue":"23","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,12,14]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Phosphoinositide 3-kinase-\u03b4 (PI3K\u03b4) inhibitors are active in lymphoid malignancies, although associated toxicities can limit their use. Umbralisib is a dual inhibitor of PI3K\u03b4 and casein kinase-1\u03b5 (CK1\u03b5). This study analyzed integrated comprehensive toxicity data from 4 open-label, phase 1 and 2 studies that included 371 adult patients (median age, 67 years) with relapsed\/refractory non-Hodgkin lymphoma (follicular lymphoma [n = 147]; marginal zone lymphoma [n = 82]; diffuse large B-cell lymphoma\/mantle cell lymphoma [n = 74]; chronic lymphocytic leukemia [n = 43]; and other tumor types [n = 25]) who were treated with the recommended phase 2 dose of umbralisib 800 mg or higher once daily. At data cutoff, median duration of umbralisib treatment was 5.9 months (range, 0.1-75.1 months), and 107 patients (28.8%) received umbralisib for \u226512 months. Any-grade treatment-emergent adverse events (AEs) occurred in 366 (98.7%) of 371 patients, with the most frequent being diarrhea (52.3%), nausea (41.5%), and fatigue (31.8%). Grade 3 or higher treatment-emergent AEs occurred in 189 (50.9%) of 371 patients and included neutropenia (11.3%), diarrhea (7.3%), and increased aminotransferase levels (5.7%). Treatment-emergent serious AEs occurred in 95 (25.6%) of 371 patients. AEs of special interest were limited and included pneumonia (29 of 371 [7.8%]), noninfectious colitis (9 of 371 [2.4%]), and pneumonitis (4 of 371 [1.1%]). AEs led to discontinuation of umbralisib in 51 patients (13.7%). Four patients (1.1%) died of AEs, none of which was deemed related to umbralisib. No cumulative toxicities were reported. The favorable long-term tolerability profile and low rates of immune-mediated toxicities support the potential use of umbralisib for the benefit of a broad population of patients with lymphoid malignancies.<\/jats:p>","DOI":"10.1182\/bloodadvances.2021005132","type":"journal-article","created":{"date-parts":[[2021,9,21]],"date-time":"2021-09-21T23:59:37Z","timestamp":1632268777000},"page":"5332-5343","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":22,"title":["Integrated safety analysis of umbralisib, a dual PI3K\u03b4\/CK1\u03b5 inhibitor, in relapsed\/refractory lymphoid malignancies"],"prefix":"10.1182","volume":"5","author":[{"given":"Matthew S.","family":"Davids","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Owen A.","family":"O\u2019Connor","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Virginia Cancer Center, Charlottesville, VA;"},{"name":"TG Therapeutics, Inc, New York, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1879-8084","authenticated-orcid":false,"given":"Wojciech","family":"Jurczak","sequence":"additional","affiliation":[{"name":"Maria Sk\u0142odowska-Curie National Research Institute of Oncology, Krak\u00f3w, Poland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felipe","family":"Samaniego","sequence":"additional","affiliation":[{"name":"The University of Texas M.D. Anderson Cancer Center, Houston, TX;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy S.","family":"Fenske","sequence":"additional","affiliation":[{"name":"Medical College of Wisconsin, Milwaukee, WI;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2112-2651","authenticated-orcid":false,"given":"Pier Luigi","family":"Zinzani","sequence":"additional","affiliation":[{"name":"IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia \u201cSer\u00e0gnoli,\u201d and Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale Universit\u00e0 degli Studi, Bologna, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6836-2364","authenticated-orcid":false,"given":"Manish R.","family":"Patel","sequence":"additional","affiliation":[{"name":"Florida Cancer Specialists\/Sarah Cannon Research Institute, Sarasota, FL;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nilanjan","family":"Ghosh","sequence":"additional","affiliation":[{"name":"Levine Cancer Institute, Atrium Health, Charlotte, NC;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce D.","family":"Cheson","sequence":"additional","affiliation":[{"name":"Lymphoma Research Foundation, New York, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico","family":"Derenzini","sequence":"additional","affiliation":[{"name":"Onco-Hematology Division, European Institute of Oncology IRCCS, Department of Health Sciences, University of Milan, Milan, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle M.","family":"Brander","sequence":"additional","affiliation":[{"name":"Duke University Health System, Duke Cancer Institute, Durham, NC;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James A.","family":"Reeves","sequence":"additional","affiliation":[{"name":"Florida Cancer Specialists South\/Sarah Cannon Research Institute, Fort Myers, FL;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanda","family":"Knopi\u0144ska-Pos\u0142uszny","sequence":"additional","affiliation":[{"name":"Gdynia Oncology Center, Gdynia, Poland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2088-0899","authenticated-orcid":false,"given":"John N.","family":"Allan","sequence":"additional","affiliation":[{"name":"Weill Cornell Medicine, New York, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tycel","family":"Phillips","sequence":"additional","affiliation":[{"name":"University of Michigan Comprehensive Cancer Center, Ann Arbor, MI;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1436-0464","authenticated-orcid":false,"given":"Paolo F.","family":"Caimi","sequence":"additional","affiliation":[{"name":"University Hospitals Seidman Cancer Center, Cleveland, OH;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ewa","family":"Lech-Maranda","sequence":"additional","affiliation":[{"name":"Institute of Hematology and Transfusion Medicine, Warsaw, Poland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5144-6710","authenticated-orcid":false,"given":"John M.","family":"Burke","sequence":"additional","affiliation":[{"name":"Rocky Mountain Cancer Centers\/US Oncology Research, Aurora, CO;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richy","family":"Agajanian","sequence":"additional","affiliation":[{"name":"The Oncology Institute of Hope and Innovation, Downey, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9948-660X","authenticated-orcid":false,"given":"Ruth","family":"Pettengell","sequence":"additional","affiliation":[{"name":"St. George\u2019s University of London, London, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lori A.","family":"Leslie","sequence":"additional","affiliation":[{"name":"John Theurer Cancer Center, Hackensack Meridian Health School of Medicine, Hackensack, NJ;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7988-1565","authenticated-orcid":false,"given":"Chan Y.","family":"Cheah","sequence":"additional","affiliation":[{"name":"Sir Charles Gairdner Hospital and University of Western Australia, Perth, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gustavo","family":"Fonseca","sequence":"additional","affiliation":[{"name":"Florida Cancer Specialists North\/Sarah Cannon Research Institute, St. Petersburg, FL;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Essell","sequence":"additional","affiliation":[{"name":"Oncology Hematology Care, Cincinnati, OH;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julio C.","family":"Chavez","sequence":"additional","affiliation":[{"name":"Moffitt Cancer Center, Tampa, FL;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John M.","family":"Pagel","sequence":"additional","affiliation":[{"name":"Swedish Cancer Institute, Seattle, WA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeff P.","family":"Sharman","sequence":"additional","affiliation":[{"name":"Willamette Valley Cancer Institute\/US Oncology Research, Eugene, OR; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanzhi","family":"Hsu","sequence":"additional","affiliation":[{"name":"TG Therapeutics, Inc, New York, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hari P.","family":"Miskin","sequence":"additional","affiliation":[{"name":"TG Therapeutics, Inc, New York, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Sportelli","sequence":"additional","affiliation":[{"name":"TG Therapeutics, Inc, New York, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael S.","family":"Weiss","sequence":"additional","affiliation":[{"name":"TG Therapeutics, Inc, New York, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian W.","family":"Flinn","sequence":"additional","affiliation":[{"name":"Sarah Cannon Research Institute and Tennessee Oncology, Nashville, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2021,12,9]]},"reference":[{"issue":"1","key":"2021120916263966200_B1","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/bjh.13065","article-title":"Targeting PI3-kinase (PI3K), AKT and mTOR axis in lymphoma","volume":"167","author":"Blachly","year":"2014","journal-title":"Br J Haematol."},{"issue":"5","key":"2021120916263966200_B2","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1158\/1535-7163.MCT-13-0639","article-title":"Picking the point of inhibition: a comparative review of PI3K\/AKT\/mTOR pathway inhibitors","volume":"13","author":"Dienstmann","year":"2014","journal-title":"Mol Cancer Ther."},{"issue":"4","key":"2021120916263966200_B3","doi-asserted-by":"crossref","first-page":"2236","DOI":"10.4049\/jimmunol.173.4.2236","article-title":"Cutting edge: differential roles for phosphoinositide 3-kinases, p110gamma and p110delta, in lymphocyte chemotaxis and homing","volume":"173","author":"Reif","year":"2004","journal-title":"J Immunol."},{"issue":"9","key":"2021120916263966200_B4","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1038\/s41580-019-0129-z","article-title":"PI3K isoforms in cell signalling and vesicle trafficking","volume":"20","author":"Bilanges","year":"2019","journal-title":"Nat Rev Mol Cell Biol."},{"issue":"5","key":"2021120916263966200_B5","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/nrm2882","article-title":"The emerging mechanisms of isoform-specific PI3K signalling","volume":"11","author":"Vanhaesebroeck","year":"2010","journal-title":"Nat Rev Mol Cell Biol."},{"issue":"3","key":"2021120916263966200_B6","doi-asserted-by":"crossref","first-page":"82","DOI":"10.3390\/biom9030082","article-title":"Structural determinants of isoform selectivity in PI3K inhibitors","volume":"9","author":"Miller","year":"2019","journal-title":"Biomolecules."},{"issue":"18","key":"2021120916263966200_B7","doi-asserted-by":"crossref","first-page":"3071","DOI":"10.1002\/1873-3468.12377","article-title":"p110\u03b1 and p110\u03b2 isoforms of PI3K signaling: are they two sides of the same coin?","volume":"590","author":"Singh","year":"2016","journal-title":"FEBS Lett."},{"issue":"9","key":"2021120916263966200_B8","doi-asserted-by":"crossref","first-page":"4330","DOI":"10.1073\/pnas.94.9.4330","article-title":"P110delta, a novel phosphoinositide 3-kinase in leukocytes","volume":"94","author":"Vanhaesebroeck","year":"1997","journal-title":"Proc Natl Acad Sci USA."},{"issue":"7629","key":"2021120916263966200_B9","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/nature19834","article-title":"PI3K\u03b3 is a molecular switch that controls immune suppression [published correction appears in Nature. 2017;542(7639):124]","volume":"539","author":"Kaneda","year":"2016","journal-title":"Nature."},{"issue":"9","key":"2021120916263966200_B10","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1038\/s41375-018-0012-5","article-title":"Distinct roles for phosphoinositide 3-kinases \u03b3 and \u03b4 in malignant B cell migration","volume":"32","author":"Ali","year":"2018","journal-title":"Leukemia."},{"issue":"11","key":"2021120916263966200_B11","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1056\/NEJMoa1314583","article-title":"PI3K\u03b4 inhibition by idelalisib in patients with relapsed indolent lymphoma","volume":"370","author":"Gopal","year":"2014","journal-title":"N Engl J Med."},{"issue":"35","key":"2021120916263966200_B12","doi-asserted-by":"crossref","first-page":"3898","DOI":"10.1200\/JCO.2017.75.4648","article-title":"Phosphatidylinositol 3-kinase inhibition by copanlisib in relapsed or refractory indolent lymphoma","volume":"35","author":"Dreyling","year":"2017","journal-title":"J Clin Oncol."},{"issue":"11","key":"2021120916263966200_B13","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1200\/JCO.18.00915","article-title":"DYNAMO: a phase II study of duvelisib (IPI-145) in patients with refractory indolent non-Hodgkin lymphoma [published correction appears in J Clin Oncol. 2019;37(16):1448]","volume":"37","author":"Flinn","year":"2019","journal-title":"J Clin Oncol."},{"issue":"16","key":"2021120916263966200_B14","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1200\/JCO.18.01460","article-title":"Final results of a randomized, phase III study of rituximab with or without idelalisib followed by open-label idelalisib in patients with relapsed chronic lymphocytic leukemia","volume":"37","author":"Sharman","year":"2019","journal-title":"J Clin Oncol."},{"issue":"8","key":"2021120916263966200_B15","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1182\/blood-2017-05-786566","article-title":"Duvelisib, a novel oral dual inhibitor of PI3K-\u03b4,\u03b3, is clinically active in advanced hematologic malignancies","volume":"131","author":"Flinn","year":"2018","journal-title":"Blood."},{"issue":"4","key":"2021120916263966200_B16","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1038\/s41375-020-01010-6","article-title":"A phase 1b\/2 study of duvelisib in combination with FCR (DFCR) for frontline therapy for younger CLL patients","volume":"35","author":"Davids","year":"2020","journal-title":"Leukemia."},{"issue":"9","key":"2021120916263966200_B17","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1158\/1078-0432.CCR-19-3061","article-title":"Efficacy and safety of duvelisib following disease progression on ofatumumab in patients with relapsed\/refractory CLL or SLL in the DUO Crossover Extension Study","volume":"26","author":"Davids","year":"2020","journal-title":"Clin Cancer Res."},{"key":"2021120916263966200_B18","author":"COPIKTRA\u00ae (duvelisib) [package insert]","year":"2018."},{"key":"2021120916263966200_B19","author":"ZYDELIG\u00ae (idelalisib) [package insert]","year":"2018."},{"issue":"10","key":"2021120916263966200_B20","doi-asserted-by":"crossref","first-page":"2779","DOI":"10.3109\/10428194.2015.1022770","article-title":"Management of adverse events associated with idelalisib treatment: expert panel opinion","volume":"56","author":"Coutr\u00e9","year":"2015","journal-title":"Leuk Lymphoma."},{"key":"2021120916263966200_B21","author":"ALIQOPA\u2122 (copanlisib) [package insert]","year":"2017."},{"issue":"9","key":"2021120916263966200_B22","doi-asserted-by":"crossref","first-page":"402","DOI":"10.3390\/biom9090402","article-title":"For better or worse: the potential for dose limiting the on-target toxicity of PI 3-kinase inhibitors","volume":"9","author":"Buchanan","year":"2019","journal-title":"Biomolecules."},{"issue":"2","key":"2021120916263966200_B23","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/s40264-018-0778-4","article-title":"Safety and tolerability of phosphatidylinositol-3-kinase (PI3K) inhibitors in oncology","volume":"42","author":"Curigliano","year":"2019","journal-title":"Drug Saf."},{"key":"2021120916263966200_B24","doi-asserted-by":"crossref","first-page":"x21","DOI":"10.1093\/annonc\/mdz440","article-title":"Management of toxicity to isoform \u03b1-specific PI3K inhibitors","volume":"30","author":"Nunnery","year":"2019","journal-title":"Ann Oncol."},{"issue":"4","key":"2021120916263966200_B25","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/S1470-2045(18)30082-2","article-title":"Umbralisib, a novel PI3K\u03b4 and casein kinase-1\u03b5 inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma: an open-label, phase 1, dose-escalation, first-in-human study","volume":"19","author":"Burris","year":"2018","journal-title":"Lancet Oncol."},{"issue":"1","key":"2021120916263966200_B26","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1182\/blood-2016-08-731240","article-title":"Silencing c-Myc translation as a therapeutic strategy through targeting PI3K\u03b4 and CK1\u03b5 in hematological malignancies","volume":"129","author":"Deng","year":"2017","journal-title":"Blood."},{"issue":"13","key":"2021120916263966200_B27","doi-asserted-by":"crossref","first-page":"3072","DOI":"10.1182\/bloodadvances.2020001800","article-title":"The dual PI3K\u03b4\/CK1\u03b5 inhibitor umbralisib exhibits unique immunomodulatory effects on CLL T cells","volume":"4","author":"Maharaj","year":"2020","journal-title":"Blood Adv."},{"issue":"2","key":"2021120916263966200_B28","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.immuni.2013.07.019","article-title":"Canonical Wnt signaling negatively modulates regulatory T cell function","volume":"39","author":"van Loosdregt","year":"2013","journal-title":"Immunity."},{"issue":"15","key":"2021120916263966200_B29","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1200\/JCO.20.03433","article-title":"Umbralisib, a dual PI3K\u03b4\/CK1\u03b5 inhibitor in patients with relapsed\/refractory indolent lymphoma","volume":"39","author":"Fowler","year":"2021","journal-title":"J Clin Oncol."},{"key":"2021120916263966200_B30","author":"Gribben","year":"2020"},{"key":"2021120916263966200_B31","author":"Medical Dictionary for Regulatory Activities"},{"issue":"5","key":"2021120916263966200_B32","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1093\/annonc\/mdx031","article-title":"Optimal sequencing of ibrutinib, idelalisib, and venetoclax in chronic lymphocytic leukemia: results from a multicenter study of 683 patients","volume":"28","author":"Mato","year":"2017","journal-title":"Ann Oncol."},{"key":"2021120916263966200_B33","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/978-3-319-13150-4_8","article-title":"Current therapeutic strategies and new treatment paradigms for follicular lymphoma","volume":"165","author":"Kritharis","year":"2015","journal-title":"Cancer Treat Res."},{"issue":"6","key":"2021120916263966200_B34","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.blre.2012.09.004","article-title":"Management of indolent lymphoma: where are we now and where are we going","volume":"26","author":"Lunning","year":"2012","journal-title":"Blood Rev."},{"key":"2021120916263966200_B35","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.copbio.2019.11.020","article-title":"Bispecific antibodies in cancer immunotherapy","volume":"65","author":"Rader","year":"2020","journal-title":"Curr Opin Biotechnol."},{"issue":"9","key":"2021120916263966200_B36","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.3324\/haematol.2020.272500","article-title":"Phase II study of acalabrutinib in ibrutinib-intolerant patients with relapsed\/refractory chronic lymphocytic leukemia","volume":"106","author":"Rogers","year":"2021","journal-title":"Haematologica."},{"issue":"10277","key":"2021120916263966200_B37","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/S0140-6736(21)00224-5","article-title":"Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1\/2 study","volume":"397","author":"Mato","year":"2021","journal-title":"Lancet."},{"issue":"20","key":"2021120916263966200_B38","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1182\/blood.2020007376","article-title":"Phase 2 study of the safety and efficacy of umbralisib in patients with CLL who are intolerant to BTK or PI3K\u03b4 inhibitor therapy","volume":"137","author":"Mato","year":"2021","journal-title":"Blood."},{"issue":"2","key":"2021120916263966200_B39","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1182\/blood-2016-03-707133","article-title":"Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity","volume":"128","author":"Lampson","year":"2016","journal-title":"Blood."},{"issue":"23","key":"2021120916263966200_B40","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.1182\/blood-2018-05-850461","article-title":"The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL\/SLL","volume":"132","author":"Flinn","year":"2018","journal-title":"Blood."},{"issue":"7505","key":"2021120916263966200_B41","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/nature13444","article-title":"Inactivation of PI(3)K p110\u03b4 breaks regulatory T-cell-mediated immune tolerance to cancer [published correction appears in Nature. 2016;535(7613):580]","volume":"510","author":"Ali","year":"2014","journal-title":"Nature."},{"issue":"1","key":"2021120916263966200_B42","doi-asserted-by":"crossref","first-page":"78","DOI":"10.4049\/jimmunol.2000043","article-title":"Loss of phosphatidylinositol 3-kinase activity in regulatory T cells leads to neuronal inflammation","volume":"205","author":"Stark","year":"2020","journal-title":"J Immunol."},{"issue":"8","key":"2021120916263966200_B43","doi-asserted-by":"crossref","first-page":"2940","DOI":"10.1182\/blood-2007-04-086751","article-title":"Inactivation of PI3Kgamma and PI3Kdelta distorts T-cell development and causes multiple organ inflammation","volume":"110","author":"Ji","year":"2007","journal-title":"Blood."},{"key":"2021120916263966200_B44","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.ceb.2014.08.003","article-title":"Casein kinase 1 and Wnt\/\u03b2-catenin signaling","volume":"31","author":"Cruciat","year":"2014","journal-title":"Curr Opin Cell Biol."},{"key":"2021120916263966200_B45","author":"D","year":"2018"},{"issue":"21","key":"2021120916263966200_B46","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1182\/blood.2019002118","article-title":"Ublituximab and umbralisib in relapsed\/refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia","volume":"134","author":"Lunning","year":"2019","journal-title":"Blood."},{"issue":"2","key":"2021120916263966200_B47","doi-asserted-by":"crossref","first-page":"e100","DOI":"10.1016\/S2352-3026(18)30216-3","article-title":"Tolerability and activity of ublituximab, umbralisib, and ibrutinib in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: a phase 1 dose escalation and expansion trial","volume":"6","author":"Nastoupil","year":"2019","journal-title":"Lancet Haematol."},{"issue":"1","key":"2021120916263966200_B48","doi-asserted-by":"crossref","first-page":"e38","DOI":"10.1016\/S2352-3026(18)30196-0","article-title":"Umbralisib in combination with ibrutinib in patients with relapsed or refractory chronic lymphocytic leukaemia or mantle cell lymphoma: a multicentre phase 1-1b study","volume":"6","author":"Davids","year":"2019","journal-title":"Lancet Haematol."},{"key":"2021120916263966200_B49","author":"Cheah","year":"2020"},{"key":"2021120916263966200_B50","author":"Davids","year":"2020"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/5\/23\/5332\/1850216\/advancesadv2021005132.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/5\/23\/5332\/1850216\/advancesadv2021005132.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,9]],"date-time":"2021-12-09T16:32:10Z","timestamp":1639067530000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/5\/23\/5332\/476985\/Integrated-safety-analysis-of-umbralisib-a-dual"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,9]]},"references-count":50,"journal-issue":{"issue":"23","published-print":{"date-parts":[[2021,12,14]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2021005132","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,9]]}}}